Back to Search
Start Over
Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years.
- Source :
-
Thrombosis journal [Thromb J] 2024 Mar 27; Vol. 22 (1), pp. 30. Date of Electronic Publication: 2024 Mar 27. - Publication Year :
- 2024
-
Abstract
- Background: Thromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date.<br />Methods: In this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone.<br />Results: We here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated.<br />Conclusions: We recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards.<br /> (© 2024. The Author(s).)
Details
- Language :
- English
- ISSN :
- 1477-9560
- Volume :
- 22
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Thrombosis journal
- Publication Type :
- Academic Journal
- Accession number :
- 38539225
- Full Text :
- https://doi.org/10.1186/s12959-024-00602-x